Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship Between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma by Antonelli, Alessandro et al.
E U RO P E AN URO L OGY 74 ( 2 018 ) 6 61 – 6 6 7
ava i lable at www.sciencedirect .com
journal homepage: www.europeanurology.comKidney Cancer
Below Safety Limits, Every Unit of Glomerular Filtration Rate
Counts: Assessing the Relationship Between Renal Function
and Cancer-specific Mortality in Renal Cell CarcinomaAlessandro Antonelli a,*, Andrea Minervini b, Marco Sandri c, Roberto Bertini d,
Riccardo Bertolo e, Marco Carini b, Maria Furlan a, Alessandro Larcher d, Guglielmo Mantica f,
Andrea Mari b, Francesco Montorsi d, Carlotta Palumbo a, Francesco Porpiglia e,
Paola Romagnani g, Claudio Simeone a, Carlo Terrone f, Umberto Capitanio d
aDepartment of Urology,[1_TD$DIFF] Spedali Civili Hospital, University of Brescia, Brescia, Italy; bDepartment of Urology, Careggi Hospital, University of Florence,
Florence, Italy; cData Methods and Systems Statistical Laboratory, University of Brescia, Brescia, Italy; dDivision of Experimental Oncology, Department of
Urology, URI—Urological Research Institute, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy; eDepartment of Urology,
San Luigi Gonzaga Hospital, School of Medicine, Orbassano, Turin, Italy; fDepartment of Urology, IRCCS San Martino Hospital, University of Genoa, Genoa,
Italy; gDepartment of Biomedical Experimental and Clinical Science “Mario Serio”, University of Florence, Florence, ItalyArticle info
Article history:















Background: The hypothesis that renal function could influence oncological outcomes is supported
by anecdotal literature.
Objective: To determine whether estimated glomerular ﬁltration rate (eGFR) is related to cancer-
speciﬁc mortality (CSM) in patients who had undergone surgery for renal cell carcinoma (RCC).
Design, setting, and participants: A retrospective analysis of 3457 patients who underwent radical
(39%) or partial nephrectomy (61%) for cT1–2 RCC between 1990 and 2015.
Outcome measurements and statistical analysis: The eGFR was calculated by the Chronic Kidney
Disease Epidemiology Collaboration equation. CSM was analyzed in a multivariable competing-risk
framework, estimating the subdistribution hazard ratio (SHR) accounting for deaths from other
causes. The relationship between eGFR and CSM was investigated from multiple statistical
approaches—extended Cox regression with eGFR incorporated as a time-dependent covariate,
landmark analysis, and joint modeling. Other predictors were selected by competing-risk random
forest method and backward elimination.
Results and limitations: The relationship between eGFR and CSM was graphically described by a
linear spline, [10_TD$DIFF]i.e. a continuous piecewise linear function with two lines joined by a knot. For eGFR
treated as a time-dependent covariate, the knot was located at 65 ml/min; at landmark analysis with
eGFR at the baseline, 12 mo, and last functional follow-up, the knots were 85, 60, and 65 ml/min,
respectively. In multivariable competing-risk analysis, CSMwas associatedwith eGFR only for values
of eGFR below these cutoffs, with SHRs for every 10 ml/min of reduction in eGFR of 1.25 (p = 0.003),
1.16 (p = 0.028), 1.44 (p = 0.02), and 1.16 (p = 0.042), corresponding to time-dependent eGFR, and
eGFR at baseline, 12 mo, and last functional follow-up, respectively. Joint modeling conﬁrmed these
results. A retrospective design with inherent biases in data collection represents a limitation.
Conclusions: In patients undergoing surgery for RCC, renal function should be preserved in order to
improve cancer-related survival.
Patient summary: The relationship between renal function and probability of dying due to renal
cancer is complex. The present study found a correlation between [11_TD$DIFF]glomerular [12_TD$DIFF]ﬁltration rate and
cancer [13_TD$DIFF]speciﬁc mortality that could reconsider the oncological role of renal function in patients
undergoing surgery for renal cancer.
© 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.* Corresponding author. Urology Unit, Spedali Civili Hospital, University of Brescia, Piazzale Spedali
Civili no. 1, Brescia 25127, Italy. Tel. +390303995215.
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International guidelines [1,2] recommend partial over
radical nephrectomy as the standard treatment for cT1
renal cell carcinoma (RCC) because of equivalent oncol-
ogical outcomes [3] with superior preservation of renal
function, postulated as beneficial to reduce cardiovascular
mortality [4–6]. Thus, the indication to partial nephrectomy
is progressively expanding even if the trade-off between
advantages and surgical morbidity remains under debate
[7].
The hypothesis that the amount of renal function could
influence oncological outcomes is poorly intuitive and still
neglected to date. However, at careful scrutiny within
nephrology literature, it emerges that several large longi-
tudinal population studies identified a linear inverse
relationship between estimated glomerular filtration rate
(eGFR) and cancer incidence or mortality [8–12].
If confirmed, this association would be paramount in
patients with RCC, considering that surgical treatment
directly impacts renal function. The present study analyzed
a large comprehensive dataset to investigate this hypothesis.
2. Patients and methods
Five academic tertiary institutions collected full data on patients who
consecutively underwent surgery for cT1–2, N0, and M0 (AJCC/TNM
2017) RCC from 1990 to 2015.
Indication to partial nephrectomy was clinically organ-conﬁned
tumor deemed as technically resectable by an experienced surgeon at
each institution. During the study period, the tumor size cutoff to
attempt partial nephrectomy was progressively raised from 2–3 cm to
7 cm, in accordance with the contemporary guidelines [1,2].
The eGFRwas evaluated by the Chronic KidneyDisease Epidemiology
Collaboration (CKD-EPI) equation [13] at baseline, 12 mo after surgery,
and last available follow-up, to account for complete stabilization from
the surgical insult.
Patient's life status was documented by planned controls, and causes
of death were reported as related to RCC or due to other causes;
incomplete information was supplemented by phone interviews or by
consulting hospital and administrative registries.
2.1. Statistical analysis
The relationship between eGFR and cancer-speciﬁc mortality (CSM) was
analyzed in a competing-risk framework [14], accounting for death from
other causes. Subdistribution hazard ratio (SHR) is the ratio of the
instantaneous risk at time t of having the event of death of two groups
and can be interpreted as hazard ratios (HRs) of the Cox model. As
readings were taken at three time points, two of which were ﬁxed
(baseline and 12 mo postoperatively) and the third one (last functional
follow-up) scattered along the timeline, eGFR was ﬁrst incorporated as a
time-dependent covariate in an extended Fine and Gray model [15] by
expanding data from one record per patient to one record per time
interval per patient. The results of the model were compared with those
of a landmark analysis [16] investigating the association between eGFR
and CSM by setting three landmark time points (baseline,12mo, and last
functional follow-up) and estimating a standard Fine and Graymodel for
each one with eGFR as a ﬁxed-time covariate. Selection of predictors for
all models was performed by estimating variable importance by the
random survival forest method and then by backward elimination [17].Exploratory graphswere drawn to visualize the relationship between
eGFR and CSM: scatterplots with smoothed curves estimated by local
regression (LOESS) suggested to model such a relationship by a linear
spline, that is, a continuous piecewise linear function with two lines
joined by a knot, the value of which was estimated by two different
statistical methods [18,19]. Then, ﬁnal competing-risk multivariable
models were built taking into account the piecewise relationship.
As conﬁrmatory analysis, the relationship between eGFR and CSM
was investigated by the “joint modeling” [20] approach, which
incorporated eGFR as a time-dependent covariate and accounted for
the differences between pre- and postoperative periods by joining a
linear mixed-effect model for longitudinal repeated measurements of
eGFR and a Cox model with CSM as outcome, with a binary pre/post-
covariate that differentiated between eGFR measurements before or
after surgery.
A p value of <0.05 was considered statistically signiﬁcant. Calcula-
tions were donewith Stata 13 (StataCorp, College Station, TX, USA) and R
(version 3.4.4; R Foundation for Statistical Computing, Vienna, Austria).
3. Results
The dataset included 3457 patients with cT1a/T1b/T2, N0,
M0 RCC; 1335 (39%) underwent radical nephrectomy and
2122 (61%) partial nephrectomy (Table 1).
Median functional follow-up was 61 mo (interquartile
range [IQR] 24–118) with 7381 eGFR assessments recorded
(2939 at baseline and 4442 after a minimum of 12 mo from
surgery); 40%, 35%, and 26% of patients had three, two, and
one measurement, respectively; 66% had both pre- and
postoperative measurements, 19% the preoperative one
only, and 14% the postoperative one only. Median eGFR was
78.5 (IQR 65.4–92.6) ml/min at baseline, 71.4 (IQR 54.6–
89.6) ml/min after 12 mo, and 64.4 (IQR 51.5–79.3) ml/min
at the last functional follow-up; the respective percentages
of patients at chronic kidney disease (CKD) stage 3 were
16%, 33%, and 38%.
Overall 3008 patients were alive without evidence of
recurrence (follow-up>60 mo in 48%); 128 died due to RCC
and 278 due to other causes. The estimated overall survival
rates at 60 and 120 mo were 93% and 84%, respectively.
Table 2 reports competing-risk univariate analysis: CSM
was found to be significantly associated with age, gender,
and descriptive tumor features (staging, grading, clear cell
histology, and necrosis). Notably, eGFR and the presence of
stage 3 CKD were found to be significantly related to CSM,
with SHRs of 0.70 and 1.95, respectively.
The relationship between the CSM and eGFR based on
all, baseline, 12-mo, and last available functional data—
adjusted for gender, age, pT stage, grading, and type of
surgery—was graphically investigated as exemplified by
Figs. 1 and 2, referring to the analysis of the whole data
with eGFR as time dependent. As anticipated, this
preliminary evaluation was suggested to model the
relationship by a continuous piecewise linear function
inwhich two lines are joined by a knot. The two statistical
methods applied for knot location [18,19] were consistent
in finding a cutoff of 65 ml/min with eGFR as a time-
dependent covariate, and 85, 60, and 65 ml/minwith eGFR
as a time-fixed covariate at baseline, 12 mo, and last
functional follow-up, respectively.
Table 1 – Baseline characteristics of the study cohort
Feature Value
Age (yr) Median (IQR) 62.2 (53.0–70.7)
Gender M 2329 (67%)
F 1128 (33%)
Creatinine at diagnosis (mg/dl) Median (IQR) 0.9 (0.8–1.1)
Body mass index Median (IQR) 25.7 (23.4–28.1)
Hypertension No 2041 (63%)
Controlled 1121 (34%)
Uncontrolled 106 (3%)
Diabetes No 2992 (91%)
Yes 302 (9%)
Charlson comorbidity index 0 1625 (53%)
1 651 (21%)
2 801 (26%)
Symptoms at diagnosis No 2328 (73%)
Local 810 (25%)
Systemic 48 (2%)
Clinical T stage T1a 2048 (59%)
T1b 1043 (30%)
T2 361 (11%)
Surgery type Partial nephrectomy 2122 (61%)
Radical nephrectomy 1335 (39%)
Ischemia (partial nephrectomy) No 991 (40%)
Warm 1449 (59%)
Cold 20 (1%)
Blood transfusion No 2730 (84%)
Yes 511 (16%)
Complications (Clavien-Dindo) No 2610 (82.6%)
Minor (1–2) 440 (13.9%)
Major (3–4) 98 (3.1%)
Death (5) 12 (0.4%)
Tumor diameter (cm) Median (IQR) 3.7 (2.5–5.0)





Pathological N stage N0 1141 (33%)
Nx 2300 (66%)
N+ 16 (1%)
Histological subtype Clear cell 2268 (72.1%)
Papillary 592 (18.8%)
Chromophobe 240 (7.6%)
Collecting duct 13 (0.4%)
Others 32 (1.0%)
Fuhrman's grading 1–2 2351 (77%)
3–4 692 (23%)
Sarcomatoid dedifferentiation 75 (2%)
Necrosis 534 (18%)
Positive surgical margins 86 (3%)
F = female; IQR = interquartile range; M = male.
Table 2 – Univariate estimation of the correlation between features
of the cohort and cancer-specific mortality by a Fine and Gray's
competing risk regression model
Variable SHR 95% CI p value
Age (yr, continuous) 1.38 1.15–1.67 0.001
BMI (kg/m2, continuous) 0.78 0.60–1.01 0.055
Tumor diameter (cm, continuous) 1.61 1.46–1.78 <0.001
Female gender 0.58 0.38–0.89 0.01
Hypertension 1.35 0.93–1.96 0.1
Diabetes mellitus 1.39 0.78–2.47 0.26
Charlson comorbidity index
0 1.00 – –
1 1.17 0.74–1.86 0.5
2 1.39 0.92–2.10 0.12
Clinical stage
T1a 1.00 – –
T1b 2.92 1.86–4.61 <0.001
T2 5.92 3.66–9.57 <0.001
Clear cell histological subtype 2.03 1.16–3.54 0.013
High grading 2.94 2.06–4.20 <0.001
Necrosis 2.01 1.35–3.00 0.001
Positive surgical margins 1.63 0.40–6.75 0.5
Pathological stage
T1a 1.00 – –
T1b 2.61 1.55–4.40 <0.001
T2 4.74 2.61–8.62 <0.001
T3/4 7.95 4.80–13.15 <0.001
Type of surgery
Partial nephrectomy 1.00 – –
Radical nephrectomy 4.75 2.83–7.97 <0.001
eGFR (ml/min, continuous) 0.70 0.58–0.83 <0.001
CKD stage 3 1.95 1.25–3.05 0.003
Continuous variables have been standardized.
CI = conﬁdence interval; CKD = chronic kidney disease; eGFR = estimated
glomerular ﬁltration rate; SHR = subdistribution hazard ratio.).
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inverse and linear relationship between eGFR and CSM only
below such cutoffs. In particular, for every 10 ml/min of
decrease in eGFR, the SHRwas 1.25 (95% confidence interval
[CI] 1.07–1.44, p = 0.003) below 65 ml/min for time-
dependent eGFR, 1.16 (95% CI 1.02–1.31, p = 0.028) below
85 ml/min for eGFR at baseline, 1.44 (95% CI 1.06–1.96,
p = 0.02) below 60 ml/min for eGFR at 12 mo, and 1.16 (95%
CI 1.01–1.33, p = 0.042) below 65 ml/min for eGFR at the last
functional follow-up (Table 3 and Supplementary Table 1).
A negative significant association between eGFR and
CSM only below 65 ml/min (SHR = 1.39 for a decrease in
eGFR of 10 ml/min, 95% CI 1.06–1.82, p = 0.018) was
confirmed by joint modeling (Supplementary Table 2).The analysis was replicated by splitting the cohort
according to the type of surgery: breakpoints at 65 ml/min
were estimated for both the subgroups, and a linear and
inverse relationship between eGFR and CSMwas found only
below this value (partial nephrectomy SHR 1.35 [95% CI
1.02–1.92, p = 0.038]; radical nephrectomy SHR 1.23 [95% CI
1.03–1.47, p = 0.026]).
4. Discussion
The main finding of the present study was that renal
function showed an independent relationship with CSM,
after accounting for other strong prognostic factors and
competitive causes of mortality. This relationship was
modeled by a “piecewise” linear function with a cutoff of
65 ml/min considering all data, 85 ml/min for preopera-
tive values only, and between 60 and 65 ml/min for
postoperative values only. It is likely that renal function
becomes a determinant of CSM only when a certain
degree of impairment is exceeded, according to a
“threshold effect.” In other words, the amount of renal
function over breakpoints could represent a functional
reserve within which CSM seems to be uninfluenced by
eGFR. Conversely, when the reserve is “exhausted”, any
further decline proportionally increases CSM. It is worth
remarking that this behavior is typical also for “non-
oncological” detrimental effects due to renal failure
[(Fig._1)TD$FIG]
Fig. 1 – Relationship between eGFR and CIF—a measure of CSM in competing risk framework—at 60 mo: the smoothed curve estimated by local
regression (LOESS) showed clear nonlinearity that could be approximated by a continuous piecewise linear function with two regression lines and one
knot. The value of the knot was equal to 65 ml/min, as determined by different methods. CIF = cumulative incidence function; CSM = cancer-specific
mortality; eGFR = estimated glomerular filtration rate.
[(Fig._2)TD$FIG]
Fig. 2 – According to eGFR categorized into eight intervals, the [8_TD$DIFF]graph [9_TD$DIFF]represents the respective eight CIFs—a measure of CSM in competing risk
framework—as estimated by a multivariable Fine and Gray model, setting the adjustment covariates gender, age, pT stage, and grading to their mean
values. As for Fig. 1, the graph shows the existence of a nonlinear relationship between CSM and eGFR, linearly and inversely associated with values
only below the breakpoints of 65 ml/min. CIF = cumulative incidence function; CSM = cancer-specific mortality; eGFR = estimated glomerular filtration
rate.
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as such, patients with baseline eGFR below 85 ml/min
would start within the “risk” zone where any decrease of
renal function would proportionally worsen CSM, unless
postoperative eGFR was maintained over 60–65 ml/min.
Accordingly, partial nephrectomy should be preferred.
Conversely, in patients for whom postoperative eGFRcould be secured above 60–65 ml/min, the role of surgery
seems to be less determinant and they can be good
candidates for radical nephrectomy as well. However,
caution is needed considering that the prognostic
relevance of preoperative eGFR raises the possibility that
existing comorbidities could be equally or even more
determinant than surgically induced CKD.
Table 3 – Multivariable regression Fine and Gray extended model to estimate the relationship with cancer-specific mortality accounting for
competing risks in pre- and postoperative periods
Feature SHR 95% CI p value
Gender (female vs male) 0.57 0.37–0.87 0.01
Age (yr, continuous) 1.01 0.99–1.03 0.27
Type of surgery (radical vs partial nephrectomy) 2.43 1.35–4.37 0.003
pT (T1b vs T1a) 1.86 1.07–3.24 0.03
pT (T2 vs T1a) 2.92 1.57–5.45 <0.001
pT (T3–T4 vs T1a) 3.89 2.16–7.00 <0.001
Grading (high vs low) 1.67 1.10–2.51 0.015
eGFR below breakpoint (continuous, intervals of 10 ml/min) 1.25 1.07–1.44 0.003
eGFR above breakpoint (continuous, intervals of 10 ml/min) 1.04 0.86–1.26 0.72
The eGFR was incorporated as a time-ﬁxed and time-dependent covariate in pre- and postoperative models, respectively.
Breakpoint was at 65 ml/min.
CI = conﬁdence interval; eGFR = estimated glomerular ﬁltration rate; SHR = subdistribution hazard ratio.
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[3–5,22] reported that renal function plays an independent
role on non–cancer-related mortality. Definitely, the rela-
tionship between renal function and non–cancer-related
mortality is robust and widely accepted, as also confirmed
in our dataset by a multivariable Cox regression after
accounting for several patient- and tumor-related con-
founders (HR for eGFR 0.98, 95% CI 0.98–0.99, p < 0.001;
analysis not reported).
Conversely, at present, [3_TD$DIFF] the urological community has
omitted the hypothesis that the impairment of renal
function could impact CSM, although there is evidence
that CKD, also at an initial stage, may worsen the response
against cancer. Indeed, large longitudinal population
studies showed a linear inverse relationship between
eGFR, incidence of cancer [7–11], and CSM [10,23,24], in
particular for RCC. Mok et al [23] reported a linear inverse
relationship between eGFR <45 ml/min and CSM, espe-
cially for RCC, in 367 392 patients followed for amedian of
9.8 yr. Iff et al [24] found a linear inverse relationship
between eGFR <60 ml/min and CSM in 4077 patients
followed for a median of 12.8 yr; this relationship was
more robust for breast and urinary cancers and indepen-
dent of competing causes of mortality. Weng et al [10]
found an increased risk of CSM proportional to eGFR
reduction in 123 717 Taiwanese followed for a median of
7 yr; again, this effect was more pronounced for liver,
kidney, and urinary tract cancers. [4_TD$DIFF] n addition, one
retrospective multi-institutional “urological” paper
reported worse CSM after radical nephrectomy in
200 patients with preoperative CKD when compared with
600 matched controls [25].
With respect to the existing literature, the present study
provides detailed information on treatments and patholog-
ical features, major determinants of CSM crucial to
adequately conduct survival analysis. Renal function was
longitudinally recorded during follow-up, and not only at
baseline, in order to investigate whether CSM had a
relationship with synchronous eGFR. Finally, statistical
methods and prolonged follow-up allowed for the adjust-
ment of the association between renal function and CSM for
competitive causes of mortality, especially relevant in such
population with low-risk renal cancer.Comprehensive meta-analysis of retrospective observa-
tional studies showed that partial nephrectomy had lower
CSM than radical nephrectomy, providing a 29% risk
reduction in CSM (HR 0.71, p < 0.001) [3] despite compara-
ble tumor characteristics. Such a paradoxical association
between most radical therapies and the worse oncological
outcome was also found in our results, but no causality
should be claimed since selection bias was not controlled
due to the retrospective design of studies. Nevertheless, we
attempted tomitigate this bias during the assessment of the
eGFR/CSM relationship, including several tumor-related
features in multivariable analyses, and also of the type of
surgery per se. Further subgroup analysis confirmed our
findings in patients submitted to partial or radical
nephrectomy only. Ultimately, it seems that the relationship
between eGFR and CSM was not influenced by tumor-
related features, explicitly reported or hidden behind the
type of surgery.
Our findings pose some concerns regarding the results of
previous retrospective studies comparing the oncological
outcomes of partial versus radical nephrectomy, neglecting
the role of renal function as a prognostic factor. The
hypothesis that higher preservation of renal function could
have impacted these results, by favoring the patients who
underwent partial nephrectomy due to superior preserva-
tion of renal function, should be discussed. In opposition to
these considerations, the randomized trial EORTC 30904
[26,27] reported comparable CSM after partial and radical
nephrectomy. Besides the numerous limitations of this trial
[28], it should be remarked that oncological and functional
follow-up periods were not congruent (median time 9.3 vs
6.7 yr) and that the analyses were not adjusted for
competing causes of mortality, despite a large number of
patients dying from non–cancer-related causes.
We acknowledge that the association of renal function
with prognosis after cancer surgery is not intuitive and that
the underlying causes are difficult to deduce. Nevertheless,
in patientswith decreased renal function, there is a complex
set of disorders of the adaptive immune system that has
been investigated in depth. Loss of renal function deter-
mines the onset of a vicious loop in which the immune
system is [14_TD$DIFF] both activated in a proinflammatory direction and
suppressed, finally leading to uremia-related immune
EU RO P E AN URO LOGY 74 ( 2 018 ) 6 61 – 6 6 7666deficiency [29]. More extensively, CKD causes a preferential
loss of number and function of lymphoid cells through the
loss of thymic function, attrition of telomeres, and
expandedmemory T-cell population, whichwas compatible
with the concept of premature immunological aging on the
whole [30]. Finally, it could be hypothesized that preserva-
tion of renal function promotes physical and mental health
status, and contributes to improving the host's defense
against cancer.
The present study was not devoid of limitations. The first[5_TD$DIFF]
was the retrospective design with inherent biases in data
collection, particularly concerning the proteinuria (the lack of
this information compromised a more accurate estimation of
renal damage) and the pattern of missing eGFR measure-
ments. Second, as only cT1/2 renal masses were included as
cases amenable for both partial and radical nephrectomy, for
more advanced tumors the association eGFR/CSM might be
maskedby theprevailing role of pathological adverse features.
Third, it cannot be excluded that functional impairment could
be related to CSM just because a proxy of tumor volume and
complexity[6_TD$DIFF], but due to the lack of a radiological review this
issue cannot be addressed. Fourth, the long time span of the
study impacted the surgical technique, with a shift toward
minimally invasive approaches. Finally, we claim that the
length of follow-up could be inadequate to clearly depict CSM
in a cohort of patients mainly affected by low-risk tumors,
burdened by a 5% risk of “very late” (>10 yr) recurrences [31].5. Conclusions
The relationship found between eGFR and CSM indicates
that renal function could have an oncological role in
patients undergoing surgery for RCC. Whenever feasible,
nephron-sparing approaches should be preferred, unless
extirpative surgery could equally warrant the preservation
of renal function above specific limits.
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